Navigation Links
Warner Chilcott Announces Receipt of FDA Response to Citizen Petition
Date:8/24/2010

Warner Chilcott Announces Receipt of FDA Response to Citizen Petition -- ARDEE, Ireland, Aug. 24 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals Click to view news release full screen  

Warner Chilcott Announces Receipt of FDA Response to Citizen Petition

 

ARDEE, Ireland, Aug. 24 /PRNewswire-FirstCall/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced that it has received the Food and Drug Administration's ("FDA's") response to a citizen petition it had filed regarding its ASACOL and ASACOL HD products.  In its petition, Warner Chilcott requested that the FDA (1) issue bioequivalence guidance for mesalamine delayed-release tablets, (2) not approve any abbreviated new drug applications ("ANDAs") referencing ASACOL and/or ASACOL HD unless the proposed generic product is shown to be bioequivalent based on appropriate data from a clinical efficacy endpoint study, comparative pharmacokinetic testing and rigorous in vitro dissolution testing and (3) deny any waiver of bioequivalence testing for either ASACOL or ASACOL HD based on a showing of bioequivalence in the other strength.  In its joint-response to the citizen petitions of the Company and another petitioner, the FDA has granted in part and denied in part various aspects of the citizen petitions.  The impact of the FDA's response will depend upon the particular facts of any ANDA filed referencing ASACOL and/or ASACOL HD.

A copy of the FDA's response letter is available in the Investor Relations section of the Company's website at www.wcrx.com.  In addition, the Company's citizen petition and related information and the FDA's response letter are, or will be made available, on the www.regulations.gov website.

About Warner Chilcott Warner Chilcott is a leading specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the North American and Western European pharmaceuticals markets.  The Company is fully integrated with internal resources dedicated to the development, manufacturing and promotion of its products.  WCRX-G.

Forward Looking Statements This press release contains forward-looking statements, including statements concerning our operations, our anticipated financial performance and financial condition, and our business plans and growth strategy and product development efforts.  These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," "intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.  These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties.  The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facilities that produce our products or production or regulatory problems with either third party manufacturers or API suppliers upon whom we may rely for some of our products or our own manufacturing facilities; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation, including domestic and foreign health care reform, affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; our ability to realize the anticipated opportunities from our acquisition of the global branded pharmaceuticals business from The Procter and Gamble Company; the other risks identified in our periodic filings including our Annual Report on Form 10-K for the year ended December 31, 2009, and from time-to-time in our other investor communications.

We caution you that the foregoing list of important factors is not exclusive.  In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur.  We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law.


'/>"/>

SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent
2. Dr. Mahdi B. Fawzi Joins Warner Chilcott as President, Global Research and Development
3. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
4. Warner Chilcott Announces 2010 Financial Guidance Conference Call
5. Warner Chilcott Announces Secondary Equity Offering
6. Warner Chilcott Announces Early Tender Results and Receipt of Consents from a Majority of Holders of its 8-3/4% Senior Subordinated Notes due 2015
7. Warner Chilcott Prices Secondary Equity Offering
8. Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015
9. Warner Chilcott Considers Potential Repurchase or Redemption of 8.75% Senior Subordinated Notes
10. Warner Chilcott Announces Earnings Release Date and Conference Call For First Quarter 2010 Financial Results
11. Warner Chilcott to Present at the Bank of America Merrill Lynch Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... The primary goal of this research is ... the usage of liquid biopsy. Key information the survey ... Timeframe of liquid biopsy adoption amidst future users - ... type - Sample inflow to conduct liquid biopsy tests ... and so on. - Correlation analysis of sample type ...
(Date:2/11/2016)... OAKLAND, Calif. , Feb. 11, 2016  Walgreens ... stores across 39 states and Washington, D.C. ... in a move that was commended by shareholder advocacy organization ... President at As You Sow. "Many people hold on to ... options, which can have tragic consequences." --> ...
(Date:2/11/2016)... 2016  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and other birth tissues, human skin and bone, and ... advanced products and therapies, announced today that it will ... Conference in New York , NY.  ... J. Senken , Chief Financial Officer and Chris ...
Breaking Medicine Technology:
(Date:2/12/2016)... Angeles, CA (PRWEB) , ... February 12, 2016 , ... ... With a hectic schedule, a demanding job, and no time to decompress, Rabinowitz found ... she dedicated herself to meditation for its impact on her life, implementing a 20-minute-per-day ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ... Zuckerberg San Francisco General Hospital on April 5-7. The series is a multi-day, ... new habits. The workshops cover a broad range of topics, including coaching skills, ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and CEO Kenneth Fisher ... Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare ... System. This will be the first Fisher House in Nevada, and will provide ...
(Date:2/12/2016)... ... ... Vail knee specialist Robert LaPrade, MD, PhD was named one of ... of physicians establishing, leading and partnering with ambulatory surgery centers across the United States. ... also known as an ASC, is a modern health care facility focused on providing ...
(Date:2/12/2016)... ... February 12, 2016 , ... Donor Network West, the organ procurement organization ... a partnership with San Ramon Regional Medical Center. Under the collaboration, the first of ... way to accommodate a more certain time frame for donor families for the recovery ...
Breaking Medicine News(10 mins):